Inhibition of i-NOS but not n-NOS protects rat primary cell cultures against MPP+-induced neuronal toxicity

Journal of Neural Transmission

Volumn 122, Issue 6, 2015, Pages 779-788

  Brzozowski, Monika J ^a   Jenner, Peter ^a   Rose, Sarah ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dopaminergic cells; i NOS; n NOS; Nitric oxide; Parkinson s disease; Substantia nigra

Indexed keywords

4 METHYLPYRIDINIUM; ARR 17477; GLIAL FIBRILLARY ACIDIC PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; NITRIC OXIDE SYNTHASE INHIBITOR; PYRIDINIUM DERIVATIVE; UNCLASSIFIED DRUG; 3-NITROTYROSINE; 4-METHYLPYRIDINE; AMIDINE; BENZYLAMINE DERIVATIVE; ENZYME INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; MONOCLONAL ANTIBODY; N-(3-(AMINOMETHYL)BENZYL)ACETAMIDINE; N-(4-(2-((3-CHLOROPHENYLMETHYL)AMINO)ETHYL)PHENYL)-2-THIOPHENECARBOXAMIDE; NEURONAL NITRIC OXIDE SYNTHASE; NEUROPROTECTIVE AGENT; NOS1 PROTEIN, RAT; NOS2 PROTEIN, RAT; OX-6 MONOCLONAL ANTIBODY; PICOLINE DERIVATIVE; THIOPHENE DERIVATIVE; TYROSINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL BODY; CELL COUNT; CELL DEATH; CELL MEMBRANE; CELL POPULATION; CELL SIZE; CELL STRUCTURE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; FEMALE; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; MICROGLIA; NEUROLOGIC DISEASE; NEURONAL TOXICITY; NEUROPROTECTION; NITRATIVE STRESS; NONHUMAN; PRIMARY CELL CULTURE; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; MESENCEPHALON; METABOLISM; PARKINSON DISEASE; PATHOLOGY; WISTAR RAT;

AMIDINES; ANIMALS; ANTIBODIES, MONOCLONAL; ASTROCYTES; BENZYLAMINES; CELL COUNT; CELLS, CULTURED; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLIAL FIBRILLARY ACIDIC PROTEIN; MESENCEPHALON; MICROGLIA; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE II; PARKINSON DISEASE; PICOLINES; PRIMARY CELL CULTURE; RATS, WISTAR; THIOPHENES; TYROSINE; TYROSINE 3-MONOOXYGENASE;

EID: 84930200970     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1334-8     Document Type: Article

References (37)

1. Arimoto T, Bing G (2003) Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol Dis 12:35–45
2. Bredt DS, Glatt CE, Hwang PM, Fotuhi M, Dawson TM, Snyder SH (1991) Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron 7:615–624
3. Brzozowski MJ, Alcantara SL, Iravani MM, Rose S, Jenner P (2011) The effect of nNOS inhibitors on toxin-induced cell death in dopaminergic cell lines depends on the extent of enzyme expression. Brain Res 1404:21–30
4. Castagnoli K, Palmer S, Anderson A, Bueters T, Castagnoli N Jr (1997) The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem Res Toxicol 10:364–368
5. Cui W, Zhang Z, Li W, Mak S, Hu S, Zhang H, Yuan S, Rong J, Choi TC, Lee SM, Han Y (2012) Unexpected neuronal protection of SU5416 against 1-methyl-4-phenylpyridinium ion-induced toxicity via inhibiting neuronal nitric oxide synthase. PLoS One 7:e46253
6. (+)-induced neurotoxicity via selective and direct inhibition of neuronal NOS. Br J Pharmacol 168:1201–1214
7. Czarnecka A, Lenda T, Domin H, Konieczny J, Smialowska M, Lorenc-Koci E (2013) Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: the effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine. Brain Res 1541:92–105
8. Di Matteo V, Pierucci M, Benigno A, Crescimanno G, Esposito E, Di Giovanni G (2009) Involvement of nitric oxide in nigrostriatal dopaminergic system degeneration: a neurochemical study. Ann NY Acad Sci 1155:309–315
9. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. Proc Natl Acad Sci USA 98:14669–14674
10. Fedorov R, Hartmann E, Ghosh DK, Schlichting I (2003) Structural basis for the specificity of the nitric-oxide synthase inhibitors W1400 and nomega-propyl-l-arg for the inducible and neuronal isoforms. J Biol Chem 278:45818–45825
11. Fedorov R, Vasan R, Ghosh DK, Schlichting I (2004) Structures of nitric oxide synthase isoforms complexed with the inhibitor AR-R17477 suggest a rational basis for specificity and inhibitor design. Proc Natl Acad Sci USA 101:5892–5897
12. Gao HM, Liu B, Zhang W, Hong JS (2003) Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson’s disease. FASEB J 17:1954–1956
13. Gilbert EA, Edwards RJ, Boobis AR, Rose S, Jenner P (2003) Differential expression of cytochrome P450 enzymes in cultured and intact foetal rat ventral mesencephalon. J Neural Trans 110:1091–1101
14. Gomes MZ, Raisman-Vozari R, Del Bel EA (2008) A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway. Brain Res 1203:160–169
15. Gonzalez-Hernandez T, Rodriguez M (2000) Compartmental organization and chemical profile of dopaminergic and GABAergic neurons in the substantia nigra of the rat. J Comp Neurol 421:107–135
16. Grammatopoulos TN, Outeiro TF, Hyman BT, Standaert DG (2007) Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro. Biochem Biophys Res Commun 363:846–851
17. Groc L, Jackson Hunter T, Jiang H, Bezin L, Koubi D, Corcoran GB, Levine RA (2002) Nitric oxide synthase inhibition during development: effect on apoptotic death of dopamine neurons. Brain Res Dev Brain Res 138:147–153
18. Hantraye P, Brouillet E, Ferrante R, Palfi S, Dolan R, Matthews RT, Beal MF (1996) Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 2:1017–1021
19. Hirsch EC, Hunot S, Damier P, Faucheux B (1998) Glial cells and inflammation in Parkinson’s disease: a role in neurodegeneration? Ann Neurol 44:S115–S120
20. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease. Neuroscience 72:355–363
21. Iravani MM, Kashefi K, Mander P, Rose S, Jenner P (2002) Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110:49–58
22. Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, Rey P, Guerra MJ, Labandeira-Garcia JL (2009) The inflammatory response in the MPTP model of Parkinson’s disease is mediated by brain angiotensin: relevance to progression of the disease. J Neurochem 109:656–669
23. (+) cytotoxicity. Neuroscience 231:206–215
24. Larsen TR, Soderling AS, Caidahl K, Roepstorff P, Gramsbergen JB (2008) Nitration of soluble proteins in organotypic culture models of Parkinson’s disease. Neurochem Int 52:487–494
25. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5:1403–1409
26. Madathil KS, Karuppagounder SS, Haobam R, Varghese M, Rajamma U, Mohanakumar KP (2013) Nitric oxide synthase inhibitors protect against rotenone-induced, oxidative stress mediated parkinsonism in rats. Neurochem Int 62:674–683
27. McNaught KS, Jenner P (1999) Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. J Neurochem 73:2469–2476
28. Mitkovski M, Padovan-Neto FE, Raisman-Vozari R, Ginestet L, da-Silva CA, Del-Bel EA (2012) Investigations into potential extrasynaptic communication between the dopaminergic and nitrergic systems. Front Physiol 3:372
29. Muramatsu Y, Kurosaki R, Mikami T, Michimata M, Matsubara M, Imai Y, Kato H, Itoyama Y, Araki T (2002) Therapeutic effect of neuronal nitric oxide synthase inhibitor (7-nitroindazole) against MPTP neurotoxicity in mice. Metab Brain Dis 17:169–182
30. +-induced cytotoxicity in Parkinson’s disease in vitro models. Biochem Biophys Res Commun 357:596–602
31. Pardo B, Paino CL, Casarejos MJ, Mena MA (1997) Neuronal-enriched cultures from embryonic rat ventral mesencephalon for pharmacological studies of dopamine neurons. Brain Res Brain Res Protoc 1:127–132
32. Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 93:4565–4571
33. Reiner A, Zagvazdin Y (1998) On the selectivity of 7-nitroindazole as an inhibitor of neuronal nitric oxide synthase. Trends Pharmacol Sci 19:348–350
34. Schulz JB, Matthews RT, Muqit MM, Browne SE, Beal MF (1995) Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 64:936–939
35. Shimoda K, Sauve Y, Marini A, Schwartz JP, Commissiong JW (1992) A high percentage yield of tyrosine hydroxylase-positive cells from rat E14 mesencephalic cell culture. Brain Res 586:319–331
36. Watanabe H, Muramatsu Y, Kurosaki R, Michimata M, Matsubara M, Imai Y, Araki T (2004) Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study. Eur Neuropsychopharmacol 14:93–104
37. Yuste JE, Echeverry MB, Ros-Bernal F, Gomez A, Ros CM, Campuzano CM, Fernandez-Villalba E, Herrero MT (2012) 7-Nitroindazole down-regulates dopamine/DARPP-32 signaling in neostriatal neurons in a rat model of Parkinson’s disease. Neuropharmacology 63:1258–1267